On September 20, 2023 Kyverna Therapeutics ("Kyverna"), a clinical-stage cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases, reported a non-exclusive, multi-year license and supply agreement with Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica"), a quality and innovation-led viral vector Contract and Development Manufacturing Organization (CDMO), enabling the use of LentiVector with any Kyverna product (Press release, Oxford BioMedica, SEP 20, 2023, View Source [SID1234635291]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The LentiVector platform is the first commercially approved lentiviral-based gene delivery system. The platform enables the successful development of breakthrough gene and cell-based medicines.
Kyverna’s anti-CD19 chimeric antigen receptor (CAR) T-cell therapies, KYV-101 and KYV-201, specifically target CD19, a protein expressed on the surface of B cells which are involved in various types of autoimmune diseases, including lupus nephritis. These novel therapies have the potential to offer new hope to patients who have exhausted current treatment options. Kyverna’s KYV-101 CAR T-cell product is currently being tested in a Phase 1 clinical trial in lupus nephritis in the U.S. and a Phase 1/2 trial in Germany.
"We are committed to quality and innovation. As a world-leading CDMO with expertise across all key viral vector types, we are committed to enabling our biopharma customers to discover and deliver transformative therapies", said Dr. Sebastien Ribault, chief commercial officer of Oxford Biomedica. "We are excited to work with Kyverna as an innovative leader in cell therapy for autoimmune diseases and look forward to a fruitful partnership."
"We are delighted to be working with Oxford Biomedica, a recognized leader in reliable, quality vector supply. We value Oxford Biomedica’s extensive capabilities and technologies to enable efficient and cost-effective manufacturing, which is critical in the vast market of B cell-driven autoimmune diseases that our therapies address," commented Karen Walker, chief technology officer at Kyverna.